Oculis Holding AG (OCS) Form 6-K — Nov 3, 2026
Oculis Holding AG reported Q3 2026 results with a net loss of CHF 18.2 million (EPS CHF -0.30) and a nine-month net loss of CHF 57.1 million, with R&D spending up 7% year-over-year as PIONEER-1 and PREDICT-1 trial activity ramps. The company holds CHF 210.3 million ($252.0 million) in cash and short-term assets, which management says funds operations for at least 12 months. Alongside earnings, Oculis amended its ATM sales agreement with Leerink Partners, lifting program capacity to $125 million from $100 million — a fresh dilution overhang for shareholders. During 9M 2026 the company already sold 2.25 million shares under the ATM for CHF 47.8 million gross.
Key figures
- Eps
- -0.30 (Q3 2026); -0.94 (9M 2026)
- Revenue
- CHF 7,000 (grant income, Q3 2026)
- Net Income
- CHF -18,236,000 (Q3 2026); CHF -57,058,000 (9M 2026)
- Total Assets
- CHF 232,318,000 (total equity and liabilities, Sep 30, 2026)
- Cash Position
- CHF 66,292,000 cash and equivalents; CHF 210,291,000 total cash, equivalents and short-term financial assets
- Atm program size
- $125 million
- Ga expense q3 2026
- CHF 8,591,000
- Rd expense q3 2026
- CHF 15,054,000
- Shares outstanding
- 61919609
- Accure upfront payment
- $3.8 million cash plus up to 2,050,000 shares
- Operating loss q3 2026
- CHF 23,638,000
- Atm shares sold 9m 2026
- 2250000
- Share price sep 30 2026
- $9.34 (CHF 7.79)
- Atm gross proceeds 9m 2026
- CHF 47.8 million ($61.3 million)
- Diomand trials primary endpoint
- missed in both DIAMOND-1 and DIAMOND-2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.